Potential Risks and Benefits of HIV Treatment Simplification: A Simulation Model of a Proposed Clinical Trial | Zendy

Bruce R. Schackman | Zendy; Catherine A. Scott | Zendy; Paul E. Sax | Zendy; Elena Losina | Zendy; Timothy Wilkin | Zendy; John E. McKin | Zendy; Susan Swindells | Zendy; Milton C. Weinstein | Zendy; Kenneth A. Freedberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Potential Risks and Benefits of HIV Treatment Simplification: A Simulation Model of a Proposed Clinical Trial

Author(s) -

Bruce R. Schackman,

Catherine A. Scott,

Paul E. Sax,

Elena Losina,

Timothy Wilkin,

John E. McKin,

Susan Swindells,

Milton C. Weinstein,

Kenneth A. Freedberg

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/521933

Subject(s) - medicine , life expectancy , regimen , clinical trial , adverse effect , quality of life (healthcare) , human immunodeficiency virus (hiv) , intensive care medicine , randomized controlled trial , immunology , population , nursing , environmental health

In recent studies, subjects who had achieved suppression of the human immunodeficiency virus (HIV) RNA level while receiving an initial 3-drug antiretroviral regimen successfully maintained suppression while receiving treatment with a "boosted" protease inhibitor (PI) alone. We projected the long-term outcomes of this treatment simplification strategy to inform the design of a proposed multicenter, randomized clinical trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research